GV and Alexandria have taken part in a $191m round to launch Maze Therapeutics with scientific co-founders from multiple universities such as Harvard and Stanford.
US-based biotechnology developer Maze Therapeutics launched yesterday with $191m in funding provided by a consortium featuring GV, a corporate venturing subsidiary of internet and technology conglomerate Alphabet.
Alexandria Venture Investments, the investment arm of life science real estate trust Alexandria Real Estate Equities, also participated in the round co-led by Third Rock Ventures and Arch Venture Partners.
Foresite Capital, Casdin Capital and several undisclosed investors filled out the round.
Maze Therapeutics will focus on genetic modifiers – genes that affect…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
